What Rybelsus costs, and why the savings card may not help you

Before you read. This page is about price, not about whether a medicine is right for you. It is educational and does not replace your Medication Guide, pharmacist, prescriber, or insurer. Every figure here moves without notice — treat the numbers as a starting point for questions, not as a quote. Nothing here tells you to start, stop, or change a prescription because of what it costs; that conversation belongs with your prescriber.

Quick answer

There are four ways to pay for Rybelsus in the US, and which one you land in is decided almost entirely by what insurance you have.

Retail cash price: around $1,011.57 for 30 tablets, and the same figure at 3 mg, 7 mg and 14 mg.
Commercial insurance that covers it: the savings card can bring a fill to as little as $25, capped at $100 of savings per month.
No insurance: the savings card explicitly excludes you, and there is no manufacturer cash programme for Rybelsus of the kind Ozempic and Wegovy now have.
Medicare or Medicaid: the savings card is off the table, but semaglutide was selected for Medicare price negotiation and a negotiated price takes effect 1 January 2027.

Separately, Novo Nordisk announced on 24 February 2026 that the US list price of its semaglutide medicines, Rybelsus included, drops to $675 a month on 1 January 2027. What that does to your own bill is a different question, taken up below.

Keep refill dates and doses on one timeline →

What Rybelsus costs without insurance

Around $1,011.57 for a 30-tablet supply, quoted for cash-paying customers and not valid with an insurance plan.

The useful detail is what that figure does not vary with. It is the same at 3 mg, at 7 mg and at 14 mg. Pharmacy-to-pharmacy variation is real — this is a "from" price, and the same prescription can differ by tens of dollars between two chains in one town, which is why "Rybelsus cost at Walmart" is a question people type. But the variation is between pharmacies, not between strengths, and none of it moves a four-figure number into three figures.

One thing worth being blunt about: this is a retail cash price, not the list price. List price, or wholesale acquisition cost, is what Novo Nordisk charges wholesalers before rebates and discounts. A pharmacy's cash price sits on top of it. The two get used interchangeably online and they are not the same number.

The savings card, and the line that excludes most people who need it

This is the part that catches people out, and it is stated plainly in the card's own terms.

For commercially insured patients whose plan covers Rybelsus, prescribed 7 mg or 14 mg, the programme says you may pay as little as $25, with maximum savings of $100 per 1-month prescription, $200 per 2-month prescription, or $300 per 3-month prescription. Those terms took effect on 2 January 2026.

Now read the eligibility. The offer excludes full cash-paying patients, and anyone enrolled in Medicare, Medicaid, VA, DOD or TRICARE is ineligible.

Put those two facts together and the shape of it is clear. The card is a copay reducer for people who already have coverage. It is not a discount for people who do not. If you are uninsured and searching for the cost of Rybelsus, the $25 figure you keep seeing quoted is not available to you — and the $100 monthly savings cap means that even where the card does apply, it moves a $1,000 bill by a tenth at most before your insurance does the rest.

Why Rybelsus has no cash price when Ozempic and Wegovy do

Novo Nordisk does run a direct self-pay channel, NovoCare Pharmacy. It covers Wegovy and Ozempic — self-pay was reported at $349 a month, down from $499. Rybelsus is not in it.

That absence is the single most practical thing on this page, because it is invisible unless you go looking for it. Drugs.com's price guide for Rybelsus records it from the other direction: no manufacturer promotions could be found for this medication.

The contrast with the newer oral GLP-1 is stark. Eli Lilly's Foundayo launched with self-pay tiers through LillyDirect from the start — we keep that picture current in what Foundayo costs. For a drug approved in 2019, the assumption baked into Rybelsus's pricing is that you have a commercial plan.

None of which is a reason to switch anything. The two are approved for different things — Foundayo compared with Rybelsus sets out why they are not substitutes — and price is one input to a prescribing decision, not the decision.

A refill you did not see coming is the expensive kind. Takely records which strength you are on and when the bottle was filled, so a 30-day supply does not quietly become tomorrow's problem. Open Takely in your browser →

Why the dose you are on does not change the price

Rybelsus is priced per package, not per milligram. Thirty tablets of 3 mg and thirty tablets of 14 mg carry the same figure.

This matters more than it sounds, because the label's escalation runs 3 mg for the first 30 days, then 7 mg, then 14 mg if more glycemic control is needed. On a lot of medicines that ladder would mean a rising bill. Here it does not: the starting month, which the label says is not effective for glycemic control on its own, costs what the maintenance month costs.

The corollary is that the money question and the dose question are separate. If a dose is being held because of tolerability — and gastrointestinal reactions cluster during escalation, which what the label reports dose by dose goes through — that decision does not save or cost you anything at the pharmacy. Takely will keep the refill date and the dose on one timeline so the two do not get tangled in memory.

What changes on 1 January 2027

On 24 February 2026 Novo Nordisk announced a reduction in the US list price of its semaglutide medicines to $675 per month, effective 1 January 2027. The announcement names the products explicitly: Wegovy injection 2.4 mg and tablets 25 mg, Ozempic injection 0.5 mg, 1 mg and 2 mg, and Rybelsus tablets 7 mg or 14 mg. Reported reductions are around 50% for Wegovy and around 35% for Ozempic; a separate Rybelsus percentage was not given.

Two cautions before anyone budgets around it.

First, list price is not your price. It is the number before rebates, discounts and concessions, and what you hand over at a counter is set by your plan, your deductible and your pharmacy. A list-price cut can change everything or nothing for a given person.

Second, the announcement is explicit that the change does not affect other access efforts, including direct-to-patient self-pay prices. So it is not the arrival of a Rybelsus cash programme.

If you are comparing across the semaglutide range while reading this, note that the same announcement covers Ozempic in both its forms — and which Ozempic you mean now matters, because it is sold as a tablet as well as a pen.

What if you have Medicare?

The savings card is unavailable to you. What is coming instead is the Medicare Drug Price Negotiation Program.

Semaglutide was among the 15 drugs selected in the second negotiation round, with negotiated prices taking effect 1 January 2027. Reported figures put Ozempic's negotiated price at $274 a month against a $959 list price, and the higher Wegovy doses at $385 a month. The maximum fair price was applied across the commonly used dosage forms and strengths of Ozempic, Rybelsus and Wegovy, though a Rybelsus-specific figure was not published in the coverage we could verify.

Worth keeping straight: a negotiated maximum fair price applies to Medicare. It is not a cash price, and it does not reach commercial plans or the uninsured.

Medicaid, TRICARE and VA

All three make you ineligible for the savings card, and all three set their own terms — formulary placement, prior authorisation, copay tiers — that no page can answer generically. Rybelsus is a type 2 diabetes medicine, which in practice makes coverage more straightforward than for the drugs approved for weight, but "more straightforward" is not "covered." Your plan's formulary and your pharmacist are the only reliable answer.

What we could not verify

Stating this rather than papering over it, because a pricing page that hides its gaps is worse than one that admits them.

A list price from Novo Nordisk directly. NovoCare has a page titled "explaining list price" for Rybelsus; it renders as an interactive eligibility wizard with no figure on it. The $1,011.57 above is a retail cash price from Drugs.com's price guide, not a wholesale acquisition cost, and the two are different numbers.
A Rybelsus-specific Medicare negotiated price. Coverage of the second negotiation round gives figures for Ozempic and Wegovy and confirms Rybelsus is in the same selected group, without publishing its own number in what we could check.
Pharmacy-level prices. We do not quote a Walmart, Costco or CVS figure. Those move weekly, vary by location, and a stale number here would be worse than none.

Frequently asked questions

How much does Rybelsus cost without insurance?

Around $1,011.57 for 30 tablets as a retail cash price, and the same at 3 mg, 7 mg and 14 mg. The manufacturer savings card does not apply — it excludes full cash-paying patients — and there is no Novo Nordisk self-pay programme for Rybelsus of the kind that exists for Ozempic and Wegovy.

Does the Rybelsus savings card work if I am uninsured?

No. The programme is for patients with commercial insurance that covers Rybelsus, and its terms exclude full cash-paying patients outright. People enrolled in Medicare, Medicaid, VA, DOD or TRICARE are also ineligible.

How much can the savings card actually save?

For 7 mg or 14 mg it advertises paying as little as $25, with savings capped at $100 for a 1-month prescription, $200 for 2 months, or $300 for 3 months, under terms effective 2 January 2026. The cap is the number to look at: it bounds what the card can do regardless of what your plan leaves you owing.

Is Rybelsus cheaper at Walmart?

Cash prices do vary between pharmacies, and calling two or three is worth the ten minutes. What does not vary is the strength — 3 mg, 7 mg and 14 mg carry the same price — so shopping around is about the pharmacy, not the dose. We do not publish a specific chain's price because those change too often for a page to stay honest about them.

Will Rybelsus get cheaper in 2027?

The list price does. Novo Nordisk announced on 24 February 2026 that US list price for its semaglutide medicines, Rybelsus among them, falls to $675 a month on 1 January 2027, and Medicare's negotiated prices begin the same day. Whether either reaches your own out-of-pocket cost depends on your coverage; the announcement also states it does not change direct-to-patient self-pay pricing.

Primary sources and further reading

Prices change without notice. Everything on this page was checked against the sources above on 30 August 2026. Confirm current figures with the manufacturer, your plan and your pharmacist before relying on them.